Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain
April 14, 2021 08:00 ET
|
Ocugen
MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development
March 29, 2021 08:54 ET
|
Ocugen
MALVERN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Provides Business Update and Full Year 2020 Financial Results
March 18, 2021 07:30 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81% in Phase 3 interim resultsEmergency Use Authorization pathway with U.S. regulatory...
Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update
March 12, 2021 17:45 ET
|
Ocugen
MALVERN, Pa., March 12, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure...
Ocugen Inc. to Present at Upcoming March Investor Conferences
March 08, 2021 14:50 ET
|
Ocugen
MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%
March 03, 2021 08:00 ET
|
Ocugen
Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing...
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis
February 23, 2021 07:30 ET
|
Ocugen
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
February 10, 2021 21:00 ET
|
Ocugen
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
February 07, 2021 21:44 ET
|
Ocugen
MALVERN, Pa., Feb. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market
February 02, 2021 09:27 ET
|
Ocugen; Bharat Biotech
Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US marketOcugen and Bharat Biotech to share US commercialization profits Ocugen to receive...